Chapters

Transcript

Video

Can you discuss the CAHtalyst pediatric strategies aimed at understanding whether a de-coupling of the androstenedione and glucocorticoid pathways might be a solution for reducing the burden of glucocorticoid therapy?

Can you discuss the CAHtalyst pediatric strategies aimed at understanding whether a de-coupling of the androstenedione and glucocorticoid pathways might be a solution for reducing the burden of glucocorticoid therapy?


Created by

CMEducation Resources | iQ&A Congenital Adrenal Hyperplasia (CAH) Medical Intelligence Zone 

Presenter

Phyllis W. Speiser, MD

Phyllis W. Speiser, MD

Associate Professor, Institute of Molecular Medicine
Feinstein Institutes for Medical Research
Emerita Professor, Pediatrics Donald and Barbara Zucker School of Medicine
Hofstra/Northwell
New Hyde Park, NY